国际眼科杂志
國際眼科雜誌
국제안과잡지
INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
2014年
7期
1257-1259
,共3页
王云鹏%陈梅珠%陈国苍%陈艳津
王雲鵬%陳梅珠%陳國蒼%陳豔津
왕운붕%진매주%진국창%진염진
玻璃体切割%玻璃体腔注射雷珠单抗%糖尿病性视网膜病变%临床效果
玻璃體切割%玻璃體腔註射雷珠單抗%糖尿病性視網膜病變%臨床效果
파리체절할%파리체강주사뢰주단항%당뇨병성시망막병변%림상효과
vitrectomy%intravitreal ranibizumab%diabetes retinopathy%clinical results
目的：玻璃体切割+玻璃体腔注射雷珠单抗治疗糖尿病性视网膜病变( diabetes retinopathy,DR)的临床效果观察。<br> 方法：2011-02/2013-02我院共有90例糖尿病性视网膜病变患者进行玻璃体切割手术治疗。以数字法随机分成观察组(45例)和对照组(45例)。对两组病患均进行玻璃体切割手术。观察组病患术前向玻璃体腔注射雷珠单抗,然后进行玻璃体切割术治疗糖尿病性视网膜病变。对照组病患只进行玻璃体切割手术。<br> 结果：观察组疗效为优者占比71%(32/45),优良率为89%(40/45),均显著高于对照组的51%(23/45),71%(32/45),差异均有统计学意义(均P<0.05)。观察组出血量为9.64±2.27mL,眼内压为13.64±3.27mmHg,均显著少于对照组的10.21±3.14mL,16.00±3.14mmHg,差异均有统计学意义(均P<0.05)。<br> 结论：玻璃体切割联合玻璃体腔注射雷珠单抗治疗糖尿病性视网膜病变,不仅可以减少术中出血,还能减少水肿,提升效果,安全性好,临床值得推荐。
目的：玻璃體切割+玻璃體腔註射雷珠單抗治療糖尿病性視網膜病變( diabetes retinopathy,DR)的臨床效果觀察。<br> 方法：2011-02/2013-02我院共有90例糖尿病性視網膜病變患者進行玻璃體切割手術治療。以數字法隨機分成觀察組(45例)和對照組(45例)。對兩組病患均進行玻璃體切割手術。觀察組病患術前嚮玻璃體腔註射雷珠單抗,然後進行玻璃體切割術治療糖尿病性視網膜病變。對照組病患隻進行玻璃體切割手術。<br> 結果：觀察組療效為優者佔比71%(32/45),優良率為89%(40/45),均顯著高于對照組的51%(23/45),71%(32/45),差異均有統計學意義(均P<0.05)。觀察組齣血量為9.64±2.27mL,眼內壓為13.64±3.27mmHg,均顯著少于對照組的10.21±3.14mL,16.00±3.14mmHg,差異均有統計學意義(均P<0.05)。<br> 結論：玻璃體切割聯閤玻璃體腔註射雷珠單抗治療糖尿病性視網膜病變,不僅可以減少術中齣血,還能減少水腫,提升效果,安全性好,臨床值得推薦。
목적：파리체절할+파리체강주사뢰주단항치료당뇨병성시망막병변( diabetes retinopathy,DR)적림상효과관찰。<br> 방법：2011-02/2013-02아원공유90례당뇨병성시망막병변환자진행파리체절할수술치료。이수자법수궤분성관찰조(45례)화대조조(45례)。대량조병환균진행파리체절할수술。관찰조병환술전향파리체강주사뢰주단항,연후진행파리체절할술치료당뇨병성시망막병변。대조조병환지진행파리체절할수술。<br> 결과：관찰조료효위우자점비71%(32/45),우량솔위89%(40/45),균현저고우대조조적51%(23/45),71%(32/45),차이균유통계학의의(균P<0.05)。관찰조출혈량위9.64±2.27mL,안내압위13.64±3.27mmHg,균현저소우대조조적10.21±3.14mL,16.00±3.14mmHg,차이균유통계학의의(균P<0.05)。<br> 결론：파리체절할연합파리체강주사뢰주단항치료당뇨병성시망막병변,불부가이감소술중출혈,환능감소수종,제승효과,안전성호,림상치득추천。
AlM: To observe clinical effect of vitrectomy with intravitreal ranibizumab for the treatment of diabetic retinopathy ( DR) . <br> METHODS:From February 2011 to February 2013, there were 90 cases in our hospital diabetic retinopathy patients withvitrectomy surgery. lt was randomly divided into observation group ( 45 cases ) and control group ( 45 cases ) . Two groups of patients were performed vitrectomy. Patients in observation group were injected intravitreal ranibizumab before surgery, then vitrectomy was underwent for diabetic retinopathy. Vitrectomy was only underwent in control group. <br> RESULTS:The patients in observation group with good effect accounting for 71% (32/45) and good rate was 89%(40/45 ), which were significantly higher than that in control group 51% ( 23/45 ) , 71% ( 32/45 ) . Differences were statistically significant ( P < 0. 05 ). Amount of bleeding was 9. 64 ± 2. 27mL, intraocular pressure was 13. 64 ± 3. 27mmHg. lt was significantly less than that in control group 10. 21 ± 3. 14mL, 16. 00 ± 3. 14mmHg. Differences were statistically significant (P<0. 05). <br> CONCLUSlON: The vitrectomy with intravitreal ranibizumab treatment of diabetic retinopathy can not only reduce blood loss, but also reduce edema and improve effectiveness and safety. lt's worth recommending for clinical practice.
